New Zealand’s PHARMAC Funds J&J’s Concerta, Topamax: Australia/New Zealand Regulatory Roundup
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - New Zealand's Pharmaceutical Management Agency will now fund Johnson & Johnson's Concerta (methylphenidate extended release) for the treatment of attention deficit hyperactivity disorder, beginning Sept. 1
You may also be interested in...
International Vaccine Institute Forms Partnerships To Expedite Addition Of HPV Vaccine To Asia Pacific Immunization Programs
SEOUL - The International Vaccine Institute held a symposium June 1-2 in Seoul to forge public-private partnerships to encourage governments to include the human papillomavirus to their immunization programs in Asia-Pacific and the Middle East
International Vaccine Institute Forms Partnerships To Expedite Addition Of HPV Vaccine To Asia Pacific Immunization Programs
SEOUL - The International Vaccine Institute held a symposium June 1-2 in Seoul to forge public-private partnerships to encourage governments to include the human papillomavirus to their immunization programs in Asia-Pacific and the Middle East
Merck, Indian Government In Talks For Gardasil Supplies; Aim To Enroll 600 For Mandatory Trials
MUMBAI - Merck has initiated talks with the Indian health ministry to supply Gardasil vaccines for use in government health institutions. Merck has launched the human papillomavirus vaccine Gardasil in India at half its international price and intends to make the drug available to a larger population base through the government's national immunization programs (PharmAsia News, Oct. 14, 2008)